Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Given Average Recommendation of “Moderate Buy” by Brokerages

Shares of Sangamo Therapeutics, Inc. (NASDAQ:SGMO) have been assigned an average recommendation of “Moderate Buy” from the six analysts that are presently covering the firm, Marketbeat Ratings reports. Two investment analysts have rated the stock with a hold rating and four have given a buy rating to the company. The average twelve-month price target among analysts that have covered the stock in the last year is $4.50.

A number of brokerages recently weighed in on SGMO. HC Wainwright reiterated a “buy” rating and set a $10.00 price target on shares of Sangamo Therapeutics in a research note on Monday, April 7th. Wall Street Zen downgraded shares of Sangamo Therapeutics from a “hold” rating to a “sell” rating in a report on Friday, May 30th. Royal Bank of Canada reaffirmed a “sector perform” rating and set a $2.00 price target on shares of Sangamo Therapeutics in a research note on Tuesday, March 18th. Finally, Barclays lowered their target price on shares of Sangamo Therapeutics from $9.00 to $5.00 and set an “overweight” rating for the company in a report on Wednesday, May 14th.

Sangamo Therapeutics Trading Up 5.8%

Shares of SGMO opened at $0.50 on Friday. Sangamo Therapeutics has a 12-month low of $0.30 and a 12-month high of $3.18. The firm has a 50-day moving average price of $0.63 and a 200 day moving average price of $1.16. The firm has a market capitalization of $116.63 million, a P/E ratio of -0.67 and a beta of 1.46.

Sangamo Therapeutics (NASDAQ:SGMO) last issued its quarterly earnings results on Monday, May 12th. The biopharmaceutical company reported ($0.14) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.11) by ($0.03). Sangamo Therapeutics had a negative return on equity of 264.16% and a negative net margin of 257.87%. The business had revenue of $6.44 million for the quarter, compared to analyst estimates of $7.90 million. Equities research analysts predict that Sangamo Therapeutics will post -0.46 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the company. Point72 Asset Management L.P. acquired a new stake in shares of Sangamo Therapeutics during the fourth quarter worth $2,316,000. Schonfeld Strategic Advisors LLC bought a new position in shares of Sangamo Therapeutics during the 4th quarter valued at about $1,744,000. GSA Capital Partners LLP boosted its position in shares of Sangamo Therapeutics by 2,962.2% during the 1st quarter. GSA Capital Partners LLP now owns 966,202 shares of the biopharmaceutical company’s stock valued at $634,000 after purchasing an additional 934,649 shares in the last quarter. Acuta Capital Partners LLC acquired a new position in shares of Sangamo Therapeutics in the fourth quarter worth about $755,000. Finally, Two Sigma Advisers LP acquired a new position in shares of Sangamo Therapeutics in the fourth quarter worth about $722,000. 56.93% of the stock is currently owned by hedge funds and other institutional investors.

Sangamo Therapeutics Company Profile

Sangamo Therapeutics, Inc, a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease.